^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II trial to evaluate the efficacy and safety of vemetinib (ifaxa) plus anlotinib hydrochloride (forcovil) in patients with locally advanced or metastatic non-small cell lung cancer who had disease progression after osimertinib (teresha) treatment
Excerpt:
...Patients with EGFR or T790M mutation were confirmed by different detection methods. ...
Trial ID:
Source:
Title:
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Excerpt:
...Locally confirmed T790M mutation determined from biopsy (preferred) or on circulating tumour DNA, documented in tissue, plasma or serum after disease progression on the most recent first- or second-generation EGFR TK treatment regimen....
More C2 evidence
Source:
Title:
An exploratory clinical study on the the correlation of efficacy and adverse reactions of anlotinib combined with osimertinib in the treatment of EGFR-positive advanced non-small cell lung cancer between blood concentration and population pharmacokinetics
Excerpt:
...Pathologically confirmed EGFR mutation, whether accompanied by T790M mutation or not; 8. ...
Trial ID:
Source:
Title:
Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
Excerpt:
...Patients should be confirmed acquired EGFR T790M mutation and received osimertinib as the second line treatment, and they should have the following: (1) benefit from treatment with osimertinib initially ;(2) gradual progression on osimertinib treatment as defined by minor increment of tumor burden (≥10% but <20% in the sum of target lesions)....
Trial ID:
Source:
Title:
Osimertinib plus Anlotinib as first-line treatment for coexisting EGFR mutation advanced NSCLC: a single-arm, open-label, phase II study
Excerpt:
...NSCLC Patients presenting with an EGFR activating mutation (19del or 21 L858R or T790M) according to any validated method and containing one or more of TP53, PIK3CA, KRAS, MYC, RB1 by NGS sequencing; 6. ...
Trial ID:
Less C2 evidence
Source:
Title:
A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Published date:
08/08/2023
Excerpt:
We conducted a phase II single-arm prospective clinical trial of NSCLC with EGFR T790M treated with anlotinib 12mg daily for 2 consecutive weeks and 1 week off treatment combined with osimertinib 80mg daily of a 21-day cycle….The best overall response displayed that the ORR was 48.4% (95% CI 30.6-66.6), and the DCR was 100% (95% CI 86.3-100.0).
Source:
Title:
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study
Published date:
01/12/2022
Excerpt:
...the present study was to investigate the clinical outcome and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC....The best overall response of the patients during osimertinib and anlotinib combination indicated that complete response was found in one patient, partial response was observed in 26 patients, stable disease was noted in 5 patients and progressive disease was reported in one patient. Therefore, objective response rate (ORR) of the combination regimen was 81.8% (95%CI: 64.5%–93.0%), and disease control rate (DCR) was 97.0% (95%CI: 84.2%–99.9%).
DOI:
https://doi.org/10.1111/jcpt.13591
Source:
Title:
Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
Published date:
06/30/2023
Excerpt:
...we also conducted preliminary in vitro assays to evaluate the efficacy of anlotinib and in combination with osimertinib in EGFR T790M-mutant osimertinib-resistant NSCLC cell line H1975OR. And our results indicated that anlotinib alone or combined with osimertinib showed potent cytotoxicity against H1975OR, providing a basis for further preclinical and clinical investigations.
DOI:
https://doi.org/10.1002/cam4.6232
